Trial Profile
An efficacy trial of systemic infliximab for the induction of remission in patients with recalcitrant non-infectious retinal vasculitis.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Jun 2016
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Vasculitis
- Focus Therapeutic Use
- 23 Jun 2016 New trial record